Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Immunology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a major global health concern.
• Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for ASCVD.
• Existing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively lower LDL-C but face challenges with patient adherence and dosing frequency.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of recaticimab, an Fc-engineered anti-PCSK9 monoclonal antibody with an extended half-life.
• To assess recaticimab's potential to overcome limitations of current PCSK9 inhibitors, such as frequent injections and suboptimal real-world persistence.

Main Methods:

• Recaticimab incorporates a YTE mutation (M252Y/S254T/T256E) for enhanced binding to the neonatal Fc receptor (FcRn), prolonging its half-life.
• Phase III clinical trials were conducted to assess recaticimab's efficacy in LDL-C reduction.
• Safety and tolerability profiles were evaluated in monotherapy and combination settings with statins.

Main Results:

• Recaticimab demonstrated potent and sustained reductions in LDL-C.
• The antibody was effective both as monotherapy and when used in conjunction with statins.
• Recaticimab exhibited a favorable safety and tolerability profile across the trials.

Conclusions:

• Recaticimab's YTE mutation-derived structural innovation enables ultra-long dosing intervals (up to 12 weeks), potentially improving adherence and persistence.
• While pharmacologically advantageous, the translation of these benefits into improved cardiovascular outcomes requires further investigation.
• Current evidence is primarily from Chinese populations; broader population validation, real-world adherence, cardiovascular outcomes, and cost-effectiveness studies are warranted.